Skip to main content

IQVIA Holdings Value Stock - Dividend - Research Selection

Iqvia s

ISIN: US46266C1053 , WKN: A2JSPM

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

IQVIA Holdings Inc. provides advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and related implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; virtual trials; and strategic planning and design services, as well as central laboratory, genomic, bioanalytical, ADME, discovery, and vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical affairs services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. was founded in 1982 and is headquartered in Durham, North Carolina.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Medpace: Clear Winner If China Blockade Succeeds

2024-06-04
Medpace stands out among its peers due to its growth orientation, competitive margins, and focus on next-generation therapies. Find out why MEDP stock is a Buy.

Are Investors Undervaluing IQVIA Holdings Inc. (NYSE:IQV) By 33%?

2024-06-03
Key Insights IQVIA Holdings' estimated fair value is US$325 based on 2 Stage Free Cash Flow to Equity IQVIA Holdings is...

Sell ideas in Staples and Health Care - Oppenheimer

2024-06-03
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Notable Two Hundred Day Moving Average Cross - IQV

2024-05-31
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Those who invested in IQVIA Holdings (NYSE:IQV) five years ago are up 67%

2024-05-29
The main point of investing for the long term is to make money. But more than that, you probably want to see it rise...

Here's what Wall Street experts are saying about Salesforce ahead of earnings

2024-05-29
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

IQVIA Holdings Inc. stock underperforms Wednesday when compared to competitors

2024-05-29
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

IQVIA: Potential AI Beneficiary

2024-05-28
AI-enabled drug discovery could lead to more clinical trials in the future, potentially benefiting IQVIA. See why I feel IQV stock's valuation is fairly modest.

Analysis-Weight-loss drug forecasts jump to $150 billion as supply grows

2024-05-28
As millions seek access to weight-loss drugs from Novo Nordisk and Eli Lilly, increasing supplies, possible wider usage and a growing number of would-be rivals are leading some experts to raise annual global sales forecasts for the treatments to about $150 billion by the early 2030s. "It is very unusual to have a medicine that is capturing the imagination of millions of people," said Michael Kleinrock, senior research director at healthcare analytics firm IQVIA Institute for Data Science. Most insurers do not cover the new therapies with low co-payments, but an unprecedented percentage of people are paying themselves or with coupons from drug manufacturers, he said.

IQVIA Holdings (IQV) Gets a Buy from Jefferies

2024-05-28
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.